title: Safety of Infliximab Following Live Virus Vaccination in Kawasaki Disease Patients.
abstract: No published data are available regarding infliximab use in Kawasaki disease patients with recent live virus vaccination. We investigated 38 acute Kawasaki disease patients who received infliximab within 90 days of receiving measles-mumps-rubella, varicella-zoster virus, or Rotavirus vaccines. There were no adverse events or serious infections, which suggests that infliximab use in acute Kawasaki disease patients with recent live viral vaccinations is safe.
authors.affiliation: From the *Kawasaki Disease Research Center, Department of Pediatrics, UCSD School of Medicine, La Jolla, California; and †Rady Children's Hospital San Diego, San Diego, California.
authors.forename: Aaron M
authors.initials: AM
authors.lastname: Lee
authors.forename: Jane C
authors.initials: JC
authors.lastname: Burns
authors.forename: Adriana H
authors.initials: AH
authors.lastname: Tremoulet
mesh_terms: D019433:Chickenpox Vaccine; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D000069285:Infliximab / Q000009:adverse effects* / Q000627:therapeutic use; D022542:Measles-Mumps-Rubella Vaccine; D009080:Mucocutaneous Lymph Node Syndrome / Q000188:drug therapy* / Q000453:epidemiology; D011446:Prospective Studies; D022243:Rotavirus Vaccines; D014611:Vaccination / Q000706:statistics & numerical data*
chemical_list: D019433:Chickenpox Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D022243:Rotavirus Vaccines; D000069285:Infliximab